XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2021:
Contract Asset
Contract asset, January 1, 2021$7,430 
Transferred to trade receivable of contract asset included
     in beginning of the year contract asset
(7,430)
Contract asset, net of transferred to trade receivables on contracts during the period
6,499 
Contract asset, March 31, 2021$6,499 
Contract Liability
Contract liability, January 1, 2021$11,961 
Recognition of revenue included in beginning of year contract liability
(1,677)
Contract liability, net of revenue recognized on contracts during the period1,604 
Foreign currency translation
(22)
Contract liability, March 31, 202111,866 
Schedule of Disaggregation of Revenue The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2021 and 2020 (amounts in thousands):
Three Months Ended March 31, 2021Three Months Ended March 31, 2020
Neurosurgery$189,254 $184,943 
Instruments51,987 46,497 
Total Codman Specialty Surgical241,241 231,440 
Wound Reconstruction and Care(2)
88,698 72,267 
Extremity Orthopedics(1)
— 21,472 
Private Label30,132 29,145 
Total Tissue Technologies118,830 122,884 
Total revenue$360,071 $354,324 
(1) On January 4, 2021, the Company completed its previously announced sale of its Extremity Orthopedics business to Smith & Nephew USD Limited. In conjunction with the sale of this business, the Company rebranded the Orthopedics and Tissue Technologies segment as Tissue Technologies in the first quarter of 2021. See Note 2. Acquisitions and Divestitures, for details.
(2) On January 20, 2021, the Company acquired ACell Inc. for an acquisition purchase price of $305.4 million plus contingent consideration of up to $100 million, that may be payable upon achieving certain revenue-based performance milestones in 2022, 2023 and 2025.See Note 2. Acquisitions and Divestitures, for details.